Impact of Fibroblast Growth Factor 23 (FGF-23) and Serum Phosphate on Allograft Function and Mortality in Kidney Allograft Recipients

NCT00903578 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2009-12-17

No results posted yet for this study

Summary

The present study will examine whether serum FGF-23 and serum phosphate at baseline of kidney transplant recipients can predict progression of allograft dysfunction at 3 years and all-cause mortality at 5 years.

Conditions

  • Kidney Transplantation

Sponsors & Collaborators

  • Ramathibodi Hospital

    lead OTHER

Principal Investigators

  • Sinee Disthabanchong, M.D. · Ramathibodi Hospital, Mahidol University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00903578 on ClinicalTrials.gov